Differential effects of parathyroid hormone and somatomedin-like growth factors on the sizes of proteoglycan monomers and their synthesis in rabbit costal chondrocytes in culture.
In the proteoglycans extracted from rabbit costal chondrocytes in culture, two populations of proteoglycans were distinguished by density gradient centrifugation under dissociative conditions. The major component was the faster sedimenting population (proteoglycan I), the putative 'cartilage-specific' proteoglycans, and the minor component was the slower sedimenting population (proteoglycan II). The monomeric size of proteoglycan I was closely related to the differentiation-state of chondrocytes and was a good marker of the differentiated chondrocytes. Treatment of the cultures with parathyroid hormone (PTH) induced an increase in the monomeric size of proteoglycan I. This increase was ascribed to an increase in the molecular size of the glycosaminoglycan chain in proteoglycan I. On the other hand, somatomedin-like growth factors, such as multiplication-stimulating activity (MSA) and cartilage-derived factor (CDF), did not affect the size of proteoglycan I, while they markedly stimulated the synthesis of proteoglycan I. In contrast, treatment with nonsomatomedin growth factors, such as fibroblast growth factor (FGF) and epidermal growth factor (EGF), resulted in not only a decrease in glycosaminoglycan synthesis but also a slight decrease in size of proteoglycan I. However, synthesis and size of proteoglycan II were little affected by these agents. Thus, the present study clearly shows that PTH and somatomedin-like growth factors have differential functions in bringing about the expression of the differentiated phenotype of chondrocytes: PTH influences chain elongation and termination of glycosaminoglycans in proteoglycan I, while somatomedin-like growth factors affect primarily the synthesis and secretion of proteoglycan I.
D000818:Animals; D002356:Cartilage / Q000187:drug effects* / Q000378:metabolism; D002478:Cells, Cultured; D006025:Glycosaminoglycans / Q000096:biosynthesis; D007328:Insulin / Q000494:pharmacology*; D007335:Insulin-Like Growth Factor II; D008970:Molecular Weight; D010281:Parathyroid Hormone / Q000494:pharmacology*; D010441:Peptide Chain Elongation, Translational / Q000187:drug effects; D010443:Peptide Chain Termination, Translational / Q000187:drug effects; D010455:Peptides / Q000494:pharmacology*; D011487:Protein Conformation; D011509:Proteoglycans / Q000096:biosynthesis*; D011817:Rabbits; D013002:Somatomedins / Q000494:pharmacology*
D006025:Glycosaminoglycans; D007328:Insulin; D010281:Parathyroid Hormone; D010455:Peptides; D011509:Proteoglycans; D013002:Somatomedins; D007335:Insulin-Like Growth Factor II